Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

Clinical Lipidology

Volumn 5, Issue 5, 2010, Pages 685-697

  Tavori, Hagai ^a,b,c   Rosenblat, Mira ^a   Vaya, Jacov ^b,c   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^c TEL HAI COLLEGE   (Israel)

Author keywords

atherosclerosis; carotid lesion; foam cell; HDL; lysophosphatidylcholine; macrophage; oxidative stress; paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ESTERASE; FATTY ACID; FIBRINOGEN; GLUCONOLACTONASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXIDASE; PHOSPHOLIPID; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CATALYSIS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; DISEASE COURSE; ENZYME DEFICIENCY; ENZYME LOCALIZATION; FOAM CELL; HUMAN; HYDROLYSIS; MACROPHAGE; MOLECULAR INTERACTION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

MUS;

EID: 78149429670     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.57     Document Type: Review

References (74)

1. Badimon JJ, Fuster V, Chesebro JH, Badimon L: Coronary atherosclerosis. A multifactorial disease. Circulation 87, II3-II16 (1993).
2. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785-1792 (1991).
3. Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, Milo S: Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins. Free Radic. Res. 34, 485-497 (2001).
4. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ: Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim. Biophys. Acta 1256, 141-150 (1995).
5. Mackness B, Hunt R, Durrington PN, Mackness MI: Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17, 1233-1238 (1997).
6. Aviram M: Antioxidants in restenosis and atherosclerosis. Curr. Int. Cardiol. Rep. 1, 66-78 (1999).
7. Marsillach J, Mackness M, Fransec R, Beltran R, Joven J, Camp J: Immunohistochemical analysis of paraoxonase-1,2 and 3 in human atheroma plaques. Presented at: 3rd International Conference on Paraoxnases 2008. Los Angeles, CA, USA, 7-10 September 2008.
8. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/ arylesterase gene (PON1) is one member of a multigene family. Genomics 33, 498-507 (1996).
9. Aviram M, Rosenblat M: Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr. Opin. Lipidol. 16, 393-399 (2005).
10. Khatib S, Musa R, Vaya J: An exogenous marker: a novel approach for the characterization of oxidative stress. Bioorg. Med. Chem. 15, 3661-3666 (2007).
11. Tavori H, Aviram M, Khatib S et al.: Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic. Biol. Med. 46, 607-615 (2009).
12. Aviram M, Hardak E, Vaya J et al.: Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101, 2510-2517 (2000).
13. Gallicchio L, Boyd K, Matanoski G et al.: Carotenoids and the risk of developing lung cancer: a systematic review. Am. J. Clin. Nutr. 88, 372-383 (2008).
14. Li WF, Sun CW, Cheng TJ, Chang KH, Chen CJ, Wang SL: Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan. Toxicol. Appl. Pharmacol. 236, 246-253 (2009).
15. Ibanez B, Vilahur G, Badimon JJ: Plaque progression and regression in atherothrombosis. J. Thromb. Haemost. 5(Suppl. 1), 292-299 (2007).
16. Williams KJ, Feig JE, Fisher EA: Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat. Clin. Pract. Cardiovasc. Med. 5, 91-102 (2008).
17. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34, 774-784 (2003).
18. Shih DM, Gu L, Xia YR et al.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287 (1998).
19. Rozenberg O, Shih DM, Aviram M: Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181, 9-18 (2005).
20. Adachi J, Asano M, Naito T, Ueno Y, Tatsuno Y: Chemiluminescent determination of cholesterol hydroperoxides in human erythrocyte membrane. Lipids 33, 1235-1240 (1998).
21. Billecke S, Draganov D, Counsell R et al.: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28, 1335-1342 (2000).
22. Draganov DI, La Du BN: Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369, 78-88 (2004).
23. Jakubowski H, Zhang L, Bardeguez A, Aviv A: Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ. Res. 87, 45-51 (2000).
24. Teiber JF, Draganov DI, La Du BN: Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66, 887-896 (2003).
25. Watson AD, Berliner JA, Hama SY et al.: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882-2891 (1995).
26. Rosenblat M, Gaidukov L, Khersonsky O et al.: The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281, 7657-7665 (2006).
27. Aviram M: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic. Res. 33(Suppl.), S85-S97 (2000).
28. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101, 1581-1590 (1998).
29. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7, 69-76 (1996).
30. Ahmed Z, Ravandi A, Maguire GF et al.: Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem. Biophys. Res. Commun. 290, 391-396 (2002).
31. Aviram M, Billecke S, Sorenson R et al.: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18, 1617-1624 (1998).
32. Nishio E, Watanabe Y: Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236, 289-293 (1997).
33. Rozenberg O, Aviram M: S-glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem. Biophys. Res. Commun. 351, 492-498 (2006).
34. Teiber JF, Billecke SS, La Du BN, Draganov DI: Estrogen esters as substrates for human paraoxonases. Arch. Biochem. Biophys. 461, 24-29 (2007).
35. Santanam N, Parthasarathy S: Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis 191, 272-275 (2007).
36. Fuhrman B, Gantman A, Aviram M: Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 211(1), 61-68 (2010).
37. Aronis A, Aharoni-Simon M, Madar Z, Tirosh O: Triacylglycerol-induced impairment in mitochondrial biogenesis and function in J774.2 and mouse peritoneal macrophage foam cells. Arch. Biochem. Biophys. 492, 74-81 (2009).
38. Tavori H, Khatib S, Aviram M, Vaya J: Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Bioorg. Med. Chem. 16, 7504-7509 (2008).
39. Draganov DI: Lactonases with oragnophosphatase activity: structural and evolutionary perspectives. Chem. Biol. Interact. 187(1-3), 370-372 (2010).
40. Tavori H, Vaya J, Aviram M: Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv. Exp. Med. Biol. 660, 99-111 (2010).
41. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid. Res. 46, 1239-1247 (2005).
42. Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA: HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J. Lipid. Res. 50, 716-722 (2009).
43. Karabina SA, Lehner AN, Frank E, Parthasarathy S, Santanam N: Oxidative inactivation of paraoxonase - implicatios in diabetes mellitus and atherosclerosis. Biochim. Biophys. Acta. 1725, 213-221 (2005).
44. Mackness MI, Mackness B, Durrington PN: Paraoxonase and coronary heart disease. Atheroscler. Suppl. 3, 49-55 (2002).
45. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K: Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with Type 2 diabetes. Metabolism 49, 1400-1405 (2000).
46. Dantoine TF, Debord J, Charmes JP et al.: Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9, 2082-2088 (1998).
47. Tanimoto N, Kumon Y, Suehiro T et al.: Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72, 2877-2885 (2003).
48. Costa LG, Vitalone A, Cole TB, Furlong CE: Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 69, 541-550 (2005).
49. Nguyen SD, Hung ND, Cheon-Ho P, Ree KM, Dai-Eun S: Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim. Biophys. Acta. 1790, 155-160 (2009).
50. Jaouad L, de Guise C, Berrougui H et al.: Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 185, 191-200 (2006).
51. Aviram M, Rosenblat M, Billecke S et al.: Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26, 892-904 (1999).
52. Franco-Pons N, Marsillach J, Joven J, Camps J, Closa D: Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis. J. Gastrointest. Surg. 12, 891-899 (2008).
53. Feingold KR, Memon RA, Moser AH, Grunfeld C: Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139, 307-315 (1998).
54. Efrat M, Rosenblat M, Mahmood S, Vaya J, Aviram M: Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Atherosclerosis 202, 461-469 (2009).
55. Nguyen SD, Sok DE: Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem. J. 375, 275-285 (2003).
56. Nguyen SD, Sok DE: Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids. J. Lipid Res. 45, 2211-2220 (2004).
57. Fuhrman B, Volkova N, Aviram M: Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 161, 307-316 (2002).
58. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M: Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 468-474 (2003).
59. Efrat M, Aviram M: Macrophage paraoxonase 1 (PON1) binding sites. Biochem. Biophys. Res. Commun. 376, 105-110 (2008).
60. Coleman R, Hayek T, Keidar S, Aviram M: A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice. Acta Histochem. 108, 415-424 (2006).
61. Rosenblat M, Vaya J, Shih D, Aviram M: Paraoxonase 1 (PON1) enhances HDLmediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179, 69-77 (2005).
62. Rosenblat M, Oren R, Aviram M: Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL. Biochem. Biophys. Res. Commun. 344, 1271-1277 (2006).
63. Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U: Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stressinduced caspase activation. Circulation 115, 2055-2064 (2007).
64. Ng CJ, Wadleigh DJ, Gangopadhyay A et al.: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276, 44444-44449 (2001).
65. Aviram M, Rosenblat M: Oxidative Stress in Cardiovascular Disease: Role of Oxidized Lipoproteins in Macrophage Foam Cell Formation in Atherosclerosis. Marcel Dekker, NY, USA, 557-590 (2004).
66. Rozenberg O, Shih DM, Aviram M: Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23, 461-467 (2003).
67. Fuhrman B, Shiner M, Volkova N, Aviram M: Cell-induced copper ion-mediated low density lipoprotein oxidation increases during in vivo monocyte-to-macrophage differentiation. Free Radic. Biol. Med. 37, 259-271 (2004).
68. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002).
69. Jessup W, Gelissen IC, Gaus K, Kritharides L: Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 17, 247-257 (2006).
70. Gaidukov L, Tawfik DS: High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA-I. Biochemistry 44, 11843-11854 (2005).
71. Harel M, Aharoni A, Gaidukov L et al.: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11, 412-419 (2004).
72. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS: The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 47, 2492-2502 (2006).
73. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1-16 (2002).
74. Nofer JR, Levkau B, Wolinska I et al.: Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276, 34480-34485 (2001).